Back to Search
Start Over
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.
- Source :
- British Journal of Cancer; 8/24/2010, Vol. 103 Issue 5, p607-612, 6p, 5 Charts, 1 Graph
- Publication Year :
- 2010
-
Abstract
- <bold>Background and Methods: </bold>Novel approaches to treat chemo-refractory metastatic breast cancer (MBC) are currently under investigation. This retrospective series reviews the outcome of 70 MBC patients who have participated in 30 phase I trials at the Royal Marsden Hospital from 2002 to 2009.<bold>Results: </bold>The median treatment lines before phase I trial entry for MBC was 5 (range: 1-12 lines). The overall response rate was 11.4% (95% CI: 4.0-18.9%) and the clinical benefit rate at 4 months was 20% (95% CI: 10.6-29.3). The median time to progression was 7.0 weeks (95% CI: 6.4-7.5) and median overall survival was 8.7 months (95% CI: 7.6-9.8) from start of first phase I treatment. No patients discontinued trial because of treatment-related toxicities. Abnormal lactate dehydrogenase, serum albumin <35 mg per 100 ml, >or=5 previous treatment lines, liver metastases and Eastern Cooperative Group performance status >or=2 at study entry were significantly associated with poor overall survival in multivariate analysis.<bold>Conclusion: </bold>This retrospective analysis provides evidence that patients with MBC tolerate phase I clinical trials and a significant proportion of patients with chemo-refractory disease, particularly those with triple-negative or Her2-positive breast cancer, may benefit from treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- BREAST cancer research
RETROSPECTIVE studies
CANCER treatment
METASTASIS
LACTATE dehydrogenase
SERUM albumin
CLINICAL trials
ANTINEOPLASTIC agents
BREAST tumors
COMPARATIVE studies
DRUG resistance in cancer cells
RESEARCH methodology
MEDICAL cooperation
RESEARCH
RESEARCH funding
EVALUATION research
TREATMENT effectiveness
Subjects
Details
- Language :
- English
- ISSN :
- 00070920
- Volume :
- 103
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- British Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 53060164
- Full Text :
- https://doi.org/10.1038/sj.bjc.6605812